What does it do?
OptiBiotix Health PLC (LON:OPTI) has developed technologies that modulate the human microbiome – the collective genome of the microbes in the body. It has done so by creating microbial strains, compounds and formulations for use in food ingredients, supplements and active compounds that can impact on human physiology, deriving potential health benefits.
With an established pipeline of microbiome modulators, the firm is working on the prevention and management of chronic lifestyle diseases such as obesity, hypercholesterolemia and lipid profiles and diabetes.
Its product roster includes weight management lines SlimBiome and SlimBiome Medical, LPLDL (cholesterol) and SweetBiotix (sweetener).
Recognised as key player
OptiBiotix has also been highlighted as a "key player" in a report on the status of the human microbiome market and its global outlook for 2020-2024.
The report from Market Study Report LLC (MSR) said over recent years the human microbiome market, which was valued at US$351.8mln in 2018, has witnessed “considerable growth on the back of rising incidences of diabetes, growing geriatric population, and continuous research and development conducted by pharmaceutical manufacturers and academia”.
“In addition, growing sedentary lifestyle, increasing incidence of diabetes and chronic diseases globally have contributed to the growth rate of Human Microbiome market”, the report said, adding that these factors were “anticipated to provide higher momentum to the market growth” in the coming years.
The report also predicted that “increasing collaboration in the industry between market players and academia to generate data and treatment for the diseases including gut related problems which can be tackled with the help of microbiota” will facilitate the growth of the market.
How it is doing
In June the life sciences firm launched WellBiome, a blend of fibres and minerals to promote the diversity of the gut microbiome, defined as an evolution of its SlimBiome.
Since then, four existing clients signed up to include the new product in their commercial collaboration.
The first half saw all of its divisions make progress towards its goal of being profitable this year: the functional fibres division reported a profit during this period, the ProBiotix division was profitable in three of the six months, and the consumer health division was profitable in one of the six months, OptioBiotix told investors.
Total invoiced sales of LPLDL and SlimBiome as an ingredient or final product shot up by 398% to £741,504 from £148,818 in the first half of last year.
What the boss says: Stephen O’Hara, chief executive officer
"There is now a trend showing an acceleration in year-on-year revenue growth as more agreements generate revenues, existing partners grow sales and more retail partners launch products. We anticipate further revenue growth in 2020 as interest in the microbiome and products for health and wellbeing grows."
"Whilst uncertainty within the global economic environment will create challenges we believe our strategy of working with multiple partners, across different application areas and geographies within the healthcare sector, will limit the risk related to any individual deal, product, or geography."